Search court records - party Matthew Solow, page 3

COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

Docket 17/40,751, U.S. Patent Application (Sept. 23, 2020)

Art Group	1629
Case Type	Utility - 514/299000
Class	514
Inventor	Nadiya Sydorenko
Inventor	Suresh Babu
Inventor	Anuradha Bhattacharyya
...

Cite Docket

Analyze

Search within this case
Find cases with Party
- Nadiya Sydorenko
Find cases with Firm
- Hoffmann & Baron

Covered Business Method Patent Review of U.S. Pat. 5,424,944

Docket CBM2013-00040, Patent Trial and Appeal Board (Aug. 2, 2013)

Kevin Turner, Matthew Clements, Sally Medley, presiding

05/11/2016	05/11/2016 05-11-2016-Board Board Trial Certificate None: Trial Certificate Issued - May 11, 2016 (PUBLIC)
02/05/2014	02/05/2014 02-05-2014-Board Board Institution Decision None: Institution Decision (PUBLIC), Board Notice None: Scheduling Order (PUBLIC)
08/02/2013	08/02/2013 08-02-2013-Petitioner Petitioner Petition None: Petition for CBM Review (PUBLIC), Petitioner Power of Attorney None: Power of Attorney (PUBLIC), Petitioner Notice None: Related Matte...

Cite Docket

Analyze

Search within this case
Analyze Judge
Analyze Party
- Dell
- Disposition Services
Analyze Firm

44 Termination Decision Document: Termination Decision Document

Document IPR2019-00451, No. 44 Termination Decision Document - Termination Decision Document (P.T.A.B. Aug. 6, 2020)

First, Patent Owner, with supporting testimony from Dr. Gizurarson, asserts that “the formulation of a benzodiazepine for intranasal administration is a difficult and complex science requiring a higher skill set and knowledge than a POSA with a bachelor’s degree ‘with several years of experience.’” Id. at 15 (citing Ex. 2012 ¶¶ 28–29).

Specifically, according to Patent Owner and Dr. Gizurarson, “the POSA would be working against physiological constraints of active ingredient uptake due to the nasal anatomy, as well as the very low solubility of benzodiazepines in formulating the pharmaceutical composition disclosed in the ’876 patent.” Id. at 15–16 (citing Ex. 2012 ¶¶ 28–29).

In order to satisfy the written description requirement, the blaze marks directing the skilled artisan to that tree must be in the originally filed disclosure.”); Fujikawa v. Wattanasin, 93 F.3d 1559, 1571 (Fed. Cir. 1996) (“In the absence of such blazemarks, simply describing a large genus of compounds

Motivation to combine/reasonable expectation of success Petitioner argues that, since neither Gwozdz nor Meezan ’962 provide specific dosing regimens for benzodiazepines/diazepam, one of ordinary skill in the art would look to the similar reference of Cartt ’784, titled “Nasal Administration of Benzodiazepines,” for these teachings.

On this record, and upon review of Petitioner’s arguments and supporting evidence, we determine that Petitioner sufficiently explains why one of ordinary skill in the art would have looked to Cartt ’784’s disclosure when seeking dosing regimens for the compositions disclosed in Gwozdz and Meezan ’962, and would have had a reasonable expectation of success in achieving the claimed invention.

Cite Document

Analyze

Search within this case
Analyze Judge
Analyze Party
- Neurelis
Analyze Firm
- Wilson Sonsini Goodrich & Rosati

TRANSLARNA

Docket 90020103, Trademark (June 25, 2020)

Class	Pharmaceutical preparations for the treatment of genetic disorders; 006; 018; 044; 046; 051; 052
Marks	TRANSLARNA
Owner at Publication	PTC Therapeutics, Inc.